A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant
- PMID: 8771007
A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant
Abstract
Sustained growth retardation in spite of a successful renal transplantation (RTx) is a serious problem for many pediatric allograft recipients. Biosynthetic growth hormone (GH) was given to 11 prepubertal children with severe growth retardation after RTx in a placebo-controlled double-blind study, assessing its effect on height velocity (HV), bone maturation, renal function, plasma IGF-I and IGF-II, serum IGF-binding proteins (IGFBP), and lipid and carbohydrate metabolism. Six months of GH (4 IU/m2/day s.c.) was either preceded or followed by six months of placebo. The patients underwent a full examination every three months. All children completed the study. Mean HV improved significantly with GH therapy (P < 0.0001), but there was also some improvement with placebo (P = 0.06). The GH-induced HV increment exceeded that of placebo by 2.9 cm/six months. Bone maturation was not accelerated. Acute renal graft rejection did not occur in any of the patients. 125I-thalamate and 131I-hippuran tests showed that mean glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) did not change significantly during GH therapy. GH caused a significant increase in IGF-I (P < 0.0001), which was far greater than the insignificant increase in serum IGFBP-3 levels (P = 0.16). Mean serum levels of total cholesterol, low density lipoprotein, apolipoprotein-A1 and -B, which are elevated at the start of the study compared with that of controls, did not change significantly during GH therapy. GH induced a significant increase in mean integrated plasma insulin levels during oral glucose tolerance test, without changing plasma glucose levels. Serum fructosamine and parathyroid hormone levels remained constant. Impressive HV increment can be achieved with GH therapy in children with growth retardation after RTx, without significant changes in renal function. Bone maturation appears unaffected, suggesting an improve final height.
Similar articles
-
Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.Clin Nephrol. 2000 Feb;53(2):99-107. Clin Nephrol. 2000. PMID: 10711411 Clinical Trial.
-
Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure.Lancet. 1991 Sep 7;338(8767):585-90. doi: 10.1016/0140-6736(91)90604-n. Lancet. 1991. PMID: 1715501 Clinical Trial.
-
Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?J Pediatr. 2002 Nov;141(5):606-10. doi: 10.1067/mpd.2002.127662. J Pediatr. 2002. PMID: 12410186
-
Derangements of the somatotropic hormone axis in chronic renal failure.Kidney Int Suppl. 1997 Mar;58:S106-13. Kidney Int Suppl. 1997. PMID: 9067957 Review.
-
Therapeutic value of recombinant human growth hormone in children with chronic renal failure.Miner Electrolyte Metab. 1992;18(2-5):320-4. Miner Electrolyte Metab. 1992. PMID: 1465083 Review.
Cited by
-
Growth after renal transplantation.Pediatr Nephrol. 2009 Jul;24(7):1297-306. doi: 10.1007/s00467-008-0787-0. Epub 2008 Mar 26. Pediatr Nephrol. 2009. PMID: 18365255 Free PMC article. Review.
-
Effectiveness of rhGH treatment on final height of renal-transplant recipients in childhood.Pediatr Nephrol. 2012 Jun;27(6):1005-9. doi: 10.1007/s00467-011-2090-8. Epub 2012 Jan 26. Pediatr Nephrol. 2012. PMID: 22278170
-
Corticosteroid avoidance in pediatric renal transplantation: can it be achieved?Paediatr Drugs. 2004;6(5):273-87. doi: 10.2165/00148581-200406050-00002. Paediatr Drugs. 2004. PMID: 15449967 Review.
-
Corticosteroid avoidance in pediatric renal transplantation.Pediatr Nephrol. 2005 Mar;20(3):418-26. doi: 10.1007/s00467-004-1786-4. Epub 2005 Feb 3. Pediatr Nephrol. 2005. PMID: 15690189 Review.
-
Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration.J Endocrinol Invest. 2018 Mar;41(3):325-331. doi: 10.1007/s40618-017-0745-4. Epub 2017 Aug 17. J Endocrinol Invest. 2018. PMID: 28819753
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous